drugset / Trial / NCT02785068

Evaluation of MM-151 + Nal-IRI + 5-FU + Leucovorin in RAS/RAF Wild-type Metastatic Colorectal Cancer

NCT02785068

Phase 1/2 Withdrawn Merrimack Pharmaceuticals
NaSingle-groupOpen-labelTreatment

Summary

A phase 1b/2a study evaluating the combination of MM-151 + nal-IRI + 5-FU + Leucovorin in RAS/RAF wild-type Metastatic Colorectal Cancer.

Timeline

Start
2016-07
Primary completion
2018-05
Completion
2018-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Irinotecan Sucrosofate Other / unclassified 70 mg/m2
Subject MM-151 Unknown
Background Leucovorin Small molecule 400 mg/m2
Background fluorouracil Small molecule 2400 mg/m2

Indications